Risk of hepatitis with various reintroduction regimens of anti-tubercular therapy: a systematic review and network meta-analysis

References

• Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO
   Google Scholar
• Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(Suppl2):S231–79.
   PubMedGoogle Scholar
• Santha T, Nazareth O, Krishnamurthy MS, et al. Treatment of pulmonary tuberculosis with short course chemotherapy in south India–5-year follow up. Tubercle. 1989;70(4):229–234.
   PubMedGoogle Scholar
• Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: a randomized clinical trial. JAMA Intern Med. 2018;178(4):485–493.
   PubMed Web of Science ®Google Scholar
• Chang KC, Leung CC, Yew WW, et al. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Eur Respir J. 2007;29(2):347–351.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment–induced hepatotoxicity. Clinl Infect Dis. 2010;50(6):833–839.
   PubMed Web of Science ®Google Scholar
• Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128(1):116–123.
   PubMed Web of Science ®Google Scholar
• Menzies D, Dion M-J, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445–449.
   PubMed Web of Science ®Google Scholar
• Zenner D, Beer N, Harris RJ, et al. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–255.
   PubMed Web of Science ®Google Scholar
• Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991;99(2):465–471.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention of drug-resistant tuberculosis. Rich M, Jaramillo E, editors. In: Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: WHO Press; 2014:7–14.
   Google Scholar
• Abbara A, Chitty S, Roe JK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 2017;17(1):231.
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther. 1975;18(1):70–79.
   PubMed Web of Science ®Google Scholar
• Huang Y-S, Chern H-D, Su W-J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4):883–889.
   PubMed Web of Science ®Google Scholar
• Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–450.
   PubMedGoogle Scholar
• Byrne JA, Strautnieks SS, Mieli-Vergani G, et al. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002;123(5):1649–1658.
   PubMed Web of Science ®Google Scholar
• Shih T-Y, Pai C-Y, Yang P, et al. A novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother. 2013;57(4):1685–1690.
   PubMed Web of Science ®Google Scholar
• Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations. Thorax. 1998;53(7):536–548.
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952.
   PubMed Web of Science ®Google Scholar
• Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol. 1996;22(3):211–214.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane methods. Cochrane database of systematic reviews. 2016;10 (Suppl 1). DOI: doi.org/10.1002/14651858.CD201601.
   Google Scholar
• Valkenhoef GV, Kuiper J. gemtc: network meta-analysis using bayesian methods. John Wiley & Sons, Ltd; 2016. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine. 21, 21 2313-24 (2002)
   Google Scholar
• Plummer M. rjags: Bayesian graphical models using MCMC. R package version 4-8. 2018 [cited 2019 Dec 25]. Available from: https://CRAN.R-project.org/package=rjags
   Google Scholar
• Plummer M JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. In Proceedings of the third international workshop on distributed statistical computing 124, 10 (2003), Vienna.
   Google Scholar
• Zuberi BF, Zuberi FF, Bader N, et al. Comparison of British Thoracic Society and American Thoracic Society reintroduction guidelines for anti-tuberculous therapy induced liver injury. J Pak Med Assoc. 2014;64(8):896–899.
   PubMed Web of Science ®Google Scholar
• Meena A, Daga MK, Kar P. Reintroduction regimens in anti-tubercular therapy-induced hepatitis in extra-pulmonary tuberculosis patients – A pilot study. Indian J Med Specialities. 2017;8(1):13–16.
   Web of Science ®Google Scholar
• Tahaoğlu K, Ataç G, Sevim T, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2001;5(1):65–69.
   PubMed Web of Science ®Google Scholar
• Dhiman RK, Saraswat VA, Rajekar H, et al. A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol. 2012;2(3):260–270.
   PubMedGoogle Scholar